ASH Annual Meeting and Exposition | Conference

Dr. Goy on CAR-Modified T Cells in Lymphoma

December 13th 2013

Andre Goy, MD, MS, from the John Theurer Cancer Center, discusses the apparent effectiveness of CD19-targeted CAR-modified T cells as a treatment for patients with various types of lymphoma.

Brentuximab Vedotin Shows Activity in B-Cell Lymphomas

December 12th 2013

Brentuximab vedotin has demonstrated antitumor activity in the setting of relapsed or refractory DLBCL across a broad range of CD30 expression, including low or undetectable CD30 expression.

Dr. Shah on Novel Therapies for Multiple Myeloma

December 11th 2013

Jatin J. Shah, MD, from the University of Texas, MD Anderson Cancer Center, describes his excitement over novel therapeutics in development for patients with multiple myeloma.

Latest Data Further Support Ibrutinib's Efficacy in CLL

December 11th 2013

Several trials of ibrutinib, an oral BTK inhibitor, either alone or in combination with currently used therapies for patients with chronic lymphocytic leukemia were presented at the 55th Annual Meeting of the American Society of Hematology.

Dr. Furman on Avoiding Chemotherapy With Idelalisib

December 10th 2013

Richard R. Furman, MD, from the New York Weill Cornell Medical Center, discusses the ability to avoid the administration of chemotherapy when using novel agents, such as idelalisib, to treat patients with chronic lymphocytic leukemia.

Telomerase Inhibitor Imetelstat Shows Promise in Myelofibrosis

December 10th 2013

Imetelstat, a telomerase inhibitor, has demonstrated significant activity in myelofibrosis, including complete responses.

New Drug Class Shows Activity in Refractory Multiple Myeloma

December 10th 2013

The first-in-class targeted agent filanesib has demonstrated promising activity in patients with relapsed and refractory multiple myeloma.

Ofatumumab Improves Response Rates, PFS in Elderly/Unfit Patients With CLL

December 10th 2013

Adding ofatumumab to chlorambucil in patients with previously untreated chronic lymphocytic leukemia who are considered inappropriate for fludarabine improves clinical outcomes and is tolerable irrespective of patient age or fitness.

Dr. Laubach on the Efficacy of Daratumumab in Myeloma

December 10th 2013

Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, discusses responses observed following the administration of daratumumab for patients with multiple myeloma.

Dr. Flinn Discusses the Efficacy of IPI-145 in CLL

December 9th 2013

Ian W. Flinn, MD, PhD, from the Sarah Cannon Research Institute, discusses the preliminary efficacy of IPI-145 in patients with chronic lymphocyic leukemia (CLL).

Ibrutinib Induces Rapid, Durable Responses in WaldenstrÃ¶m's Macroglobulinemia

December 9th 2013

The BTK inhibitor ibrutinib rapidly reduced serum immunoglobulin M levels and improved hematocrit levels in patients with relapsed or refractory WaldenstrÃ¶m's macroglobulinemia, and the responses to ibrutinib were durable.

IPI-145 Has Activity in Relapsed/Refractory CLL

December 9th 2013

Almost half of patients with relapsed or refractory chronic lymphocytic leukemia attained objective responses when treated with an oral inhibitor of phosphoinositide-3-kinase-delta and -gamma.

Bcl-2 Inhibitor ABT-199 Shows Promise in CLL and SLL

December 9th 2013

ABT-199, an orally bioavailable selective inhibitor of the Bcl-2 protein as monotherapy, induced remissions in patients with relapsed/refractory CLL and SLL, including adverse-risk subsets of patients.

Continuous Lenalidomide Deemed a Standard of Care For Newly Diagnosed Multiple Myeloma

December 9th 2013

The combination of continuous lenalidomide and low-dose dexamethasone extends PFS and trends toward improving OS compared with the standard MPT in patients with transplant-ineligible newly diagnosed multiple myeloma.

Obinutuzumab Regimen Slows CLL Compared With Rituximab

December 9th 2013

Patients with chronic lymphocytic leukemia and major comorbidities had significantly better outcomes when treated with the anti-CD20 monoclonal antibody obinutuzumab instead of rituximab.

Engineered T-Cells Achieve Dramatic Results in Resistant CLL

December 8th 2013

Treatment with engineered donor T cells led to substantial tumor regression in patients with posttransplant relapsed B-cell malignancies, results of a small clinical study showed.

Dr. Goede on Obinutuzumab Versus Rituximab in CLL

December 8th 2013

Valentin Goede, MD, from the University Hospital Cologne, discusses the efficacy findings from the stage 2 CLL11 study that examined obinutuzumab plus chlorambucil in patients with chronic lymphocytic leukemia with comorbidities.

Treating Precursor Disease May Stall Multiple Myeloma Progression

December 8th 2013

Intervention in early or "smoldering" myeloma with a three-drug regimen led to complete responses in a group of high-risk patients, suggesting a window of opportunity that may delay or prevent progression to a debilitating disease state.

Longer Bortezomib Duration Linked to Improved Survival in Multiple Myeloma

December 8th 2013

A higher cumulative dose of bortezomib, including a longer duration of treatment and/or higher dose intensity, appears to improve OS in patients with previously untreated multiple myeloma.

Dr. Brown on Idelalisib Plus Rituximab in CLL

December 8th 2013

Jennifer Brown, MD, PhD, from the Dana-Farber Cancer Institute, discusses the development of the novel PI3K-delta inhibitor idelalisib as a treatment for patients with chronic lymphocytic leukemia.